Amgenvs.Incyte
AMGN vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 9.9× larger than Incyte by market cap; Incyte trades at the lower P/E (14.0 vs 25.5); year to date, Amgen leads (+23.0% vs +14.9%).
Side by side
| AMGN | INCY | |
|---|---|---|
| Market cap | $223B | $22.5B |
| Price | $407.44 | $112.75 |
| Today | −1.4% | −0.6% |
| Return YTD | +23.0% | +14.9% |
| Return 1Y | +36.9% | +30.1% |
| Since June 26, 2026 | +13.7% | −0.9% |
| P/E | 25.5 | 14.0 |
| P/S | 5.9 | 3.9 |
| P/B | 19.1 | 3.5 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →More AMGN & INCY comparisons
Other head-to-heads in the Biotech & innovation segment.